^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dovitinib (TKI258) (FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells
Published date:
10/25/2021
Excerpt:
In this study, dovitinib was chemically modified and converted into CRBN-recruiting PROTAC...which showed enhanced antiproliferative effects against FLT3-ITD+ AML cells, both in vitro and in vivo...Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells
DOI:
https://doi.org/10.1021/acs.jmedchem.1c00996
